Enfusion Stock Analysis
ENFN Stock | USD 9.38 0.08 0.86% |
Enfusion is fairly valued with Real Value of 9.63 and Target Price of 10.17. The main objective of Enfusion stock analysis is to determine its intrinsic value, which is an estimate of what Enfusion is worth, separate from its market price. There are two main types of Enfusion's stock analysis: fundamental analysis and technical analysis.
The Enfusion stock is traded in the USA on New York Stock Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Enfusion is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Enfusion Stock trading window is adjusted to America/New York timezone.
Enfusion |
Enfusion Stock Analysis Notes
About 96.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 2.35. Enfusion had not issued any dividends in recent years. Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. Enfusion Inc. was incorporated in 2021 and is headquartered in Chicago, Illinois. Enfusion Inc operates under SoftwareApplication classification in the United States and is traded on New York Stock Exchange. It employs 892 people. To learn more about Enfusion call the company at 312 253 9800 or check out https://www.enfusion.com.Enfusion Quarterly Total Revenue |
|
Enfusion Investment Alerts
Enfusion is unlikely to experience financial distress in the next 2 years | |
Enfusion has a very strong financial position based on the latest SEC filings | |
Over 96.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from thelincolnianonline.com: Enfusion Announces Positive Financial Results for Q3 2024 |
Enfusion Upcoming and Recent Events
Earnings reports are used by Enfusion to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
5th of March 2024 Upcoming Quarterly Report | View | |
14th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
5th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Enfusion Largest EPS Surprises
Earnings surprises can significantly impact Enfusion's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2024-11-05 | 2024-09-30 | 0.06 | 0.05 | -0.01 | 16 | ||
2024-08-06 | 2024-06-30 | 0.06 | 0.05 | -0.01 | 16 | ||
2024-03-12 | 2023-12-31 | 0.05 | 0.04 | -0.01 | 20 |
Enfusion Environmental, Social, and Governance (ESG) Scores
Enfusion's ESG score is a quantitative measure that evaluates Enfusion's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Enfusion's operations that may have significant financial implications and affect Enfusion's stock price as well as guide investors towards more socially responsible investments.
Enfusion Stock Institutional Investors
Shares | T. Rowe Price Investment Management,inc. | 2024-06-30 | 1.4 M | Next Century Growth Investors Llc | 2024-06-30 | 1.1 M | Geode Capital Management, Llc | 2024-06-30 | 959 K | State Street Corp | 2024-06-30 | 931.2 K | Wellington Management Company Llp | 2024-06-30 | 915.3 K | Scalar Gauge Management, Llc | 2024-06-30 | 613.5 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 580.6 K | Bank Of America Corp | 2024-06-30 | 579.7 K | Impax Asset Management Group Plc | 2024-06-30 | 540 K | Iconiq Capital, Llc | 2024-06-30 | 14 M | Brown Capital Management, Llc | 2024-06-30 | 8.6 M |
Enfusion Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 877.66 M.Enfusion Profitablity
The company has Profit Margin (PM) of 0.02 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.06 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.06.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.06 | 0.06 | |
Return On Capital Employed | 0.13 | 0.14 | |
Return On Assets | 0.06 | 0.06 | |
Return On Equity | 0.11 | 0.12 |
Management Efficiency
Enfusion has return on total asset (ROA) of 0.0592 % which means that it generated a profit of $0.0592 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0548 %, meaning that it created $0.0548 on every $100 dollars invested by stockholders. Enfusion's management efficiency ratios could be used to measure how well Enfusion manages its routine affairs as well as how well it operates its assets and liabilities. As of the 9th of November 2024, Return On Tangible Assets is likely to grow to 0.06. Also, Return On Capital Employed is likely to grow to 0.14. At this time, Enfusion's Net Tangible Assets are very stable compared to the past year. As of the 9th of November 2024, Return On Tangible Assets is likely to grow to 0.06, while Total Assets are likely to drop about 88.2 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 0.88 | 0.92 | |
Tangible Book Value Per Share | 0.88 | 0.92 | |
Enterprise Value Over EBITDA | 40.68 | 71.39 | |
Price Book Value Ratio | 15.94 | 16.74 | |
Enterprise Value Multiple | 40.68 | 71.39 | |
Price Fair Value | 15.94 | 16.74 | |
Enterprise Value | 960.7 M | 1.9 B |
The strategic decisions made by Enfusion management significantly impact its financial stability and market performance. Evaluating these factors helps determine whether the stock is a worthwhile investment.
Operating Margin 0.0583 | Profit Margin 0.017 | Beta 0.934 | Return On Assets 0.0592 | Return On Equity 0.0548 |
Technical Drivers
As of the 9th of November, Enfusion shows the Downside Deviation of 1.7, mean deviation of 1.49, and Coefficient Of Variation of 694.19. Enfusion technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Enfusion Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Enfusion middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Enfusion. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Enfusion Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Enfusion insiders, such as employees or executives, is commonly permitted as long as it does not rely on Enfusion's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Enfusion insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Enfusion Outstanding Bonds
Enfusion issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Enfusion uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Enfusion bonds can be classified according to their maturity, which is the date when Enfusion has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
US292845AE48 Corp BondUS292845AE48 | View | |
ENFRAG 5375 30 DEC 30 Corp BondUS29280LAA17 | View | |
ENELIM 71 14 OCT 27 Corp BondUS29280HAA05 | View | |
ENELIM 2875 12 JUL 41 Corp BondUS29280HAB87 | View |
Enfusion Predictive Daily Indicators
Enfusion intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Enfusion stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Enfusion Corporate Filings
8K | 4th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 29th of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 25th of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 24th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 12th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 6th of September 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 6th of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 25th of July 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Enfusion Forecast Models
Enfusion's time-series forecasting models are one of many Enfusion's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Enfusion's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Enfusion Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Enfusion prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Enfusion shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Enfusion. By using and applying Enfusion Stock analysis, traders can create a robust methodology for identifying Enfusion entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | 0.07 | 0.07 | |
Operating Profit Margin | 0.07 | 0.07 | |
Net Profit Margin | 0.03 | 0.04 | |
Gross Profit Margin | 0.67 | 0.77 |
Current Enfusion Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Enfusion analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Enfusion analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
10.17 | Buy | 9 | Odds |
Most Enfusion analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Enfusion stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Enfusion, talking to its executives and customers, or listening to Enfusion conference calls.
Enfusion Stock Analysis Indicators
Enfusion stock analysis indicators help investors evaluate how Enfusion stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Enfusion shares will generate the highest return on investment. By understating and applying Enfusion stock analysis, traders can identify Enfusion position entry and exit signals to maximize returns.
Begin Period Cash Flow | 62.5 M | |
Common Stock Shares Outstanding | 129.4 M | |
Total Stockholder Equity | 53.7 M | |
Tax Provision | 1.4 M | |
Quarterly Earnings Growth Y O Y | -0.271 | |
Property Plant And Equipment Net | 32.6 M | |
Cash And Short Term Investments | 35.6 M | |
Cash | 35.6 M | |
Accounts Payable | 2.2 M | |
Net Debt | -20.2 M | |
50 Day M A | 8.792 | |
Total Current Liabilities | 20.3 M | |
Other Operating Expenses | 162.6 M | |
Non Current Assets Total | 39.1 M | |
Forward Price Earnings | 41.1523 | |
Non Currrent Assets Other | 6.5 M | |
Stock Based Compensation | 7.5 M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enfusion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enfusion. If investors know Enfusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enfusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.27) | Earnings Share 0.04 | Revenue Per Share 2.155 | Quarterly Revenue Growth 0.154 | Return On Assets 0.0592 |
The market value of Enfusion is measured differently than its book value, which is the value of Enfusion that is recorded on the company's balance sheet. Investors also form their own opinion of Enfusion's value that differs from its market value or its book value, called intrinsic value, which is Enfusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enfusion's market value can be influenced by many factors that don't directly affect Enfusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enfusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enfusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enfusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.